作者
Turgay Saritas, Sebastian Reinartz, Thilo Krüger, Markus Ketteler, Orfeas Liangos, Laura Labriola, Peter Stenvinkel, Christoph Kopp, Ralf Westenfeld, Pieter Evenepoel, Robert Siepmann, Stephanie Wied, Ralf-Dieter Hilgers, Leon Schurgers, Jürgen Floege
发表日期
2022/12
期刊
Clinical kidney journal
卷号
15
期号
12
页码范围
2300-2311
出版商
Oxford University Press
简介
Background
Cardiovascular calcifications are prevented by matrix Gla protein (MGP), a vitamin K–dependent protein. Haemodialysis patients exhibit marked vitamin K deficiency. The randomized, prospective, open-label, multicentre VitaVasK trial analysed whether vitamin K1 supplementation reduces progression of coronary artery calcifications (CACs) and thoracic aortic calcifications (TACs).
Methods
Patients with pre-existing CACs were randomized to continue on standard care or to additionally receive 5 mg of vitamin K1 orally thrice weekly. Hierarchically ordered primary endpoints were progression of TAC and CAC in computed tomography scans at 18 months. Linear mixed effects models with repeated measures at baseline and 12 and 18 months assessed treatment effects after adjusting for study site.
Results
Of 60 randomized patients, 20 dropped …
学术搜索中的文章
T Saritas, S Reinartz, T Krüger, M Ketteler, O Liangos… - Clinical kidney journal, 2022